This month marks ten years since CRISPR-Cas9 was repurposed as a gene editing system, so we’re looking back at what has been accomplished in a decade of CRISPR editing.
The approach, called GRAND, uses a second guide RNA to write complementary strands of DNA in targeted genomic locations, resulting in efficient insertions that can be hundreds of base pairs long.
A CRISPR-based system that reverses epigenetic changes caused by adolescent binge drinking reduces adult addiction-like behaviors in rats, a study finds, suggesting that an epigenomic approach could someday help treat people with alcohol use disorder.
A first-of-its-kind gene therapy dramatically reduced misfolded protein levels in some clinical trial participants for up to six months and reduced levels in all participants for up to a year.
The US Patent and Trademark Office has once again decided that the institute has priority over the University of California and collaborators regarding intellectual property rights for CRISPR-Cas9 gene editing in eukaryotes. But the fight over the technique isn’t over.
Geckos injected with neural stem cells modified to block cartilage growth developed the skeletal and nervous components normally lacking from regrown tails.